Диссертация (1141348), страница 13
Текст из файла (страница 13)
P.207(21).4Handbook of drug metabolism, Second Edition / Ed. by Paul G .Pearson and Larry C . Wienkers – Florida: CRC Press. 2008. 675 p.5D.F.V. Lewis, M. Dickins, P.J. Eddershaw, M.H. Tarbit, P.S.Goldfard. Cytochrome P450 Substrate Specifities, Substrate structural Templatesand Enzyme Active Site Geometries // Drug metabolism and drug interctions.1999. Vol.15. P.151.6SF. Zhou et al. Structure, function, regulation and polymorphism andthe clinical significance of human cytochrome P450 1A2.
// Drug MetabolismReview. 2010. Vol.42(2). P.268-354.7B. Wang. Synthetic and natural compounds that interact with humancytochrome P450 1A2 and implications in drug development. //CurrentMedicinal Chemistry. 2009. Vol.16 (31). P. 4066-218.8M.O'Malley et al. Effects of cigarette smoking on metabolism andeffectiveness of systemic therapy for lung cancer. // Journal of ThoracicOncology. 2014.
Vol.9(7). P.917-26.1069J. Christopher Gorski et al. The Effect of Echinacea (Echinaceapurpurea Root) on Cytochrome P450 Activity in Vivo. // Clinical Pharmacology& Therapeutics. 2004. Vol.75. P. 89-10010ZK Ali et al. CYP2C9 polymorphisms: considerations in NSAIDtherapy. // Current Opinion in Drug Discovery and Development.
2009. Vol. 12.P. 108-114.11CR Lee et al. Cytochrome P450 2C9 polymorphisms: acomprehensive review of the in-vitro and human data. // Pharmacogenetics. 2002.Vol. 12. P. 251-263.12MG Soars et al. A comparison of relative abundance, activity factorand inhibitory monoclonal antibody approaches in the characterization of humanCYP enzymology.
// British Journal of Clinical Pharmacology. 2005. Vol. 55. P.175-181.13AE Rettie et al. Clinical and toxicological relevance of CYP2C9:drug-drug interactions and pharmacogenetics. // Annual Review of Pharmacologyand Toxicology. 2005. Vol. 45. P. 477-494.14M. Pirmohamed et al. Cytochrome P450 enzyme polymorphismsand adverse drug reactions. // Toxicology. 2003. Vol. 192. P. 23-32.15I.G.Denisov et al. Structure and chemistry of cytochrome P450. //Chemical Reviews. 2005.
Vol.105(6). P.2253-2277.16T.L.Domanski et al. Phenylalanine and tryptophan scanningmutagenesis of CYP3A4 substrate recognition site residues and effect onsubstrate oxidation and cooperativity. // Biochemistry. 2001. Vol.40(34).P.10150-10160.17U.M.Zanger et al. Cytochrome P450 enzymes in drug metabolism:regulation of gene expression, enzyme activities, and impact of genetic variation.// Pharmacology and Therapeutics.
2013. Vol. 138(1). P. 103-14118C.S. Gerguson et al. Cytochrome P450 enzymes in the brain:emerging evidence of biological significance. // Trends in PharmacologicalSciences. 2011. Vol.32(12). P.708-714.10719H. Qui et al. The unique complexity of the CYP3A4 upstream regionsuggests a nongenetic explanation of its expression variability. Pharmacogeneticsand Genomics. 2010. Vol.20(3). P.167-78.20M. Ratajewski et al. Aflatoxins upregulate CYP3A4 mRNAexpression in a process that involves the PXR transcription factor.
//Toxicological Letters. 2011. Vol. 205(2). P.146-53.21Labbé L. et al. Effect of gender, sex hormones, time variables andphysiological urinary pH on apparent CYP2D6 activity as assessed by metabolicratios of marker substrates //Pharmacogenetics and Genomics. – 2000. – Т.
10. –№. 5. – С. 425-438.22relevanceV. Haufroid et al. CYP2D6 genetic polymorphisms and theirforpoisoningduetoamfetamines,opioidanalgesicsandantidepressants // Clinical Toxicology. 2015. Vol.53(6). P.501-510.23M.K. Su et al. Metabolism of classical cannabinoids and thesynthetic cannabinoid JWH-018 // Clinical Pharmacology & Therapeutics. 2015.Vol.97(6). P.562-424McGraw J, Waller D.
Cytochrome P450 variations in differentethnic populations // Expert Opinion on Drug Metabolism & Toxicology. 2012.Vol.8. P.371-382.25Grover S, Kukreti R. Functional Genetic Polymorphisms fromPhase-II Drug Metabolizing // Enzymes - CNS Neuroscience Therapy.
2012.V.18. P.705-706.26Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G et al.SuperCYP: a comprehensive database on Cytochrome P450 enzymes including atool for analysis of CYP-drug interactions // Nucleic Acids Research. 2010. V.38.P.D237-D243.27Steven L. Dubovsky. The usefulness of genotypingcytochrome P450 enzymes in the treatment of depression // Expert Opinionon Drug Metabolism & Toxicology. 2014. V.11(3). P.1-11.10828Sarah C.
Preissner et al. Polymorphic Cytochrome P450 Enzymes(CYPs) and Their Role in Personalized Therapy // PLoS One. 2013. V.8(12).P.e82562.29Shimada T. et al. Characterization of (+/-)-bufuralol hydroxylationactivities in liver microsomes of Japanese and Caucasian subjects genotyped forCYP2D6 // Pharmacogenetics. 2001. V.11(2). P.143-56.30de Leon J, Susce MT, Johnson M, Hardin M, Maw L et al. DNAmicroarray technology in the clinical environment: the AmpliChip CYP450 testfor CYP2D6 and CYP2C19 genotyping.
// CNS Spectrums. 2010. V.14. P.19-34.31Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J et al.Pharmacogenetics of antidepressants and antipsychotics: the contribution ofallelic variations to the phenotype of drug response. // Molecular Psychiatry.2004. V.9. P.442-473.32Marandi T et al. Debrisoquine and S-mephenytoin hydroxylationpolynorphisms in a Russian population living in Estonia // European Journal ofClinical Pharmacology. 1997.
V.53(3-4). P.257-260.33Metabolic Drug interactions / editors Levy R.H., Thummel K.E. etal. Lippincott Williams & Wilkins. V.2000. 793 p.34Perera V et al. Measurement of CYP1A2 activity: a focus oncaffeine as a probe // Current Drug Metabolism. 2012. V.13(5). P.667-678.35Bosilkovska M. et al. Simultaneous LC-MS/MS quantification of P-glycoprotein and cytochrome P450 probe substrates and their metabolites in DBSand plasma // Bioanalysis. 2014. V.6(2).
P.151-164.36Liu R et al. Effects of Panax notoginseng saponins on the activitiesof CYP1A2, CYP2C9, CYP2D6 and CYP3A4 in rats in vivo // PhytotherapyResearch. 2012. V.26(8) P.1113-1118.37Zadoyan G. et al. Effect of Ginkgo biloba special extract EGb 761®on human cytochrome P450 activity: a cocktail interaction study in healthyvolunteers // European Journal of Clinical Pharmacology. 2012. V.68(5) P.553560.10938Yubero-Lahoz S et al. Changes in CYP1A2 activity in humans after3,4-methylenedioxymethamphetamine (MDMA, ecstasy) administration usingcaffeine as a probe drug // Drug Metabolism and Pharmacokinetics.
2012.V.27(6). P.605-613.39Jetter A, Kinzig-Schippers M, Skott A. Cytochrome P450 2C9phenotyping using low-dose tolbutamide. // EuropeanJournalofClinicalPharmacology. 2004. V.60(3). P.165-171.40George M, Shewade DG, Kumar SV, Adithan C. Effect of anti-tuberculosis therapy on polymorphic drug metabolizing enzyme CYP2C9 usingphenytoin as a probe drug. // Indian Journal of Pharmacology. 2012. V.44(4).P.485-488.41de Andres F et al. A rapid and simple LC-MS/MS method for thesimultaneous evaluation of CYP1A2, CYP2C9, CYP2C19, CYP2D6 andCYP3A4 hydroxylation capacity. // Bioanalysis. 2014.
V.6(5). P.683-696.42Dorado P et al. Development of a HPLC method for thedetermination of losartan urinary metabolic ratio to be used for the determinationof CYP2C9 hydroxylation phenotypes.// Drug Metabolism and PersonalizedTherapy. 2012. V.27(4). P.217-233.43Frank D. Et al.
Evaluation of probe drugs and pharmacokineticmetrics for CYP2D6 phenotyping.// European Journal of Clinical Pharmacology.2007. V.63(4) P.321-333.44Bapiro TE et al. The molecular and enzyme kinetic basis for thediminished activity of the cytochrome P450 2D6.17 (CYP2D6.17) variant.Potential implications for CYP2D6 phenotyping studies and the clinical use ofCYP2D6 substrate drugs in some African populations.// BiochemicalPharmacology. 2002.
V.64(9). P.1387-1398.45Duricova J et al. Cytochrome P450 2D6 phenotype and genotype inhypertensive patients on long-term therapy with metoprolol. // Bratislava MedicalJournal. 2013. V.114(4). P.206-212.11046Chen R et al. Alternative methods for CYP2D6 phenotyping:comparison of dextromethorphan metabolic ratios from AUC, single pointplasma, and urine. // International journal of clinical pharmacology andtherapeutics.
2016. Epub47Antunes MV et al. Development, validation and clinical applicationof a HPLC-FL method for CYP2D6 phenotyping in South Brazilian breast cancerpatients. // Clinical Biochemistry. 2014. V.47(12). P.1084-1090.48Jiang XL et al. Pinoline may be used as a probe for CYP2D6activity. // Drug Metabolism & Disposition. 2009. V.37(3).
P.443-446.49Tay-Sontheimer J et al. Detection of an endogenous urinarybiomarker associated with CYP2D6 activity using global metabolomics. //Pharmacogenomics. 2014. V.15(16) P.1947-1962.50De Kesel PM. Alternative Sampling Strategies for Cytochrome P450Phenotyping. // Clinical Pharmacokinetics.
2016. V.55(2). P.169-184.51Elens L et al. Impact of POR*28 on the clinical pharmacokinetics ofCYP3A phenotyping probes midazolam and erythromycin // Pharmacogeneticsand Genomics. 2013 V.23(3). P.148-155.52Shibasaki H et al. Intraindividual and interindividual variabilities inendogenous cortisol 6β-hydroxylation clearance as an index for in vivo CYP3Aphenotyping in humans// Drug Metabolism & Disposition. 2013. V.41(2). P.475479.53Shibasaki H et al.
Use of endogenous cortisol 6β-hydroxylationclearance for phenotyping in vivo CYP3A activity in women after sequentialadministration of an oral contraceptive (OC) containing ethinylestradiol andlevonorgestrel as weak CYP3A inhibitors. // Steroids. 2014. V.87. P.137-144.54Virginie Y Martiny, Maria Miteva. Advances in MolecularModeling of Human Cytochrome P450 Polymorphism // Journal of MolecularBiology.
2013. V.7. P.207-221.11155MC Cornelis, A El-Sohemy, EK Kabagambe, Campos H. Coffee,CYP1A2 genotype, and risk of myocardial infarction // Journal of AmericanMedical Assossiation. 2006. V.295(10). P.1135(41).56Handbook of drug metabolism, Second Edition / Ed. by Paul G .Pearson and Larry C . Wienkers – Florida: CRC Press. 2008.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
